Resources Repository
-
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Evidence Synthesis | Costing Methods | Health Outcomes | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
ReportPublication 2012Mortality Risks in Environment, Health and Transport
This report presents a major meta-analysis of value of a statistical life (VSL) estimates derived …
This report presents a major meta-analysis of value of a statistical life (VSL) estimates derived from surveys around the world. The analysis seeks to explain the differences in the estimates, for example across countries. Differences in incomes and the magnitude of the risk reduction were found to be the factors having the strongest impact, but numerous other policy-relevant factors are also important. The report also presents advice on how VSL estimates can be best used…
Benefit-Cost Analysis | Preferences/Values | Policy/Regulation | Climate/Environment | College | Graduate | Critical Thinking/Analysis -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Priority Setting/Ethics | Mathematical Models | Technology Assessment | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America